Evidence map›Paper›PMID 42099775›Full record

ArticleInternational journal of genomics2026

SLC7A7 Downregulation in Monocytes Drives Immunosuppression and Osteosarcoma Progression.

Bingjie Jiang, Haoran Zhu, Zhenxing Zhang

Abstract read
In one paragraph

Article in International journal of genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bingjie JiangDepartment of Orthopedics, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang Province, China, tzc.edu.cn.
Haoran ZhuXi'an Jiaotong University Health Science Center, Xi'an, Shaanxi Province, China.
Zhenxing ZhangDepartment of Maxillofacial Surgery, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang Province, China, tzc.edu.cn.ORCID https://orcid.org/0009-0004-1812-3268

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Metabolic reprogramming and the formation of an immunosuppressive tumor microenvironment(TME) are hallmarks of osteosarcoma (OS). However, the metabolic characteristics of OS and its associated immune microenvironment remain largely unknown. Methods: The single-cell data were processed for dimensionality reduction and cell-type annotation by using the Seurat package. Pseudotime analysis and metabolic difference prediction were performed using the SCPA algorithm to predict the metabolic profiles of immune cells. Through integrative analyses using BeyondCell and scMetabolism, three distinct cancer cell subpopulations were identified. Metabolic flux potential and intercellular metabolic communication within each subpopulation were subsequently quantified using METAFlux and Mebocost. Spatial colocalization analysis and intercellular communication prediction were conducted using SpaCET and CellChat. Furthermore, qRT-PCR and survival analyses were performed on our cohort of OS patients. Results: Monocytes emerged as the predominant immune cell population within OS tissues, displaying pronounced metabolic reprogramming marked by significant upregulation of glycolysis and tryptophan metabolism. Additionally, three cancer cell subpopulations with distinct chemosensitivity profiles were identified; Subpopulation 2, characterized by high expression of CCNA2, UBE2C, and CENPF, demonstrated significantly reduced sensitivity to methotrexate, doxorubicin, cisplatin, ifosfamide, and etoposide. Moreover, both cancer cells and monocytes function as key metabolic regulators, with glutamine serving as a critical metabolic mediator. Monocytes were predominantly localized in proximity to tumor cells and exhibited activation of signaling pathways such as SPP1 and ICAM. SLC7A7 expression was significantly downregulated in OS tissues, and its expression level was correlated with patient prognosis. Furthermore, monocytes exhibiting SLC7A7 downregulation may display aberrant recruitment patterns and functional deficits, potentially playing a pivotal role in supplying glutamine to OS cells and fostering an immunosuppressive TME. Conclusions: This study provides a preliminary characterization of the metabolic landscape of OS and its associated immune microenvironment. Targeting SLC7A7-deficient monocytes may represent promising strategies for enhancing the efficacy of immunotherapy in OS.

Indexed as

chemotherapymetabolismmonocytesosteosarcomaSLC7A7

Identifiers

PMID42099775
PMCPMC13147929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.